The Use of Renal Guard System in Patients Undergoing CRT Implantation
NCT ID: NCT01936142
Last Updated: 2016-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2013-09-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Acute Kidney Injury After Transcatheter Aortic Valve Implantation
NCT04537325
Effectiveness of NephroCheckTM Test to Predict Acute Kidney Injury Following Advanced Cardiac Replacement Therapies
NCT02827448
RenalGuard System for Prevention of Contrast Induced Nephropathy
NCT02029820
Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI
NCT02793661
Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients
NCT01456013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No RenalGuard
Control group will undergo CRT implantation without using RenalGuard
No interventions assigned to this group
RenalGuard
Use of the RenalGuard system during CRT implantation
Use of RenalGuard
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Use of RenalGuard
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. estimated GFR \< 60ml/min/1.73m2
Exclusion Criteria
2. Sensitivity to Furosemide
3. Contraindication for urinary catheter
4. Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
michal roll
Head of Research and Development Division
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yoav Michowich, MD
Role: PRINCIPAL_INVESTIGATOR
Tel Aviv Sourasky MC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tel Aviv Souraky MC
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TASMC-13-0167-YMICH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.